

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

VOLUNTARY ANNOUNCEMENT

TECHNOLOGY PROMOTION AGREEMENT

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 2 July 2025, Zhongli (Hainan) Life Science Technology Co., Ltd.* (中驪(海南)生命科學技術有限公司) (“**Zhongli**”), an indirect non-wholly owned subsidiary of the Company, and Beijing Sanyouli Heze Biotechnology Co., Ltd.* (北京三有利和澤生物科技有限公司) (“**Beijing Sanyouli**”) entered into a technology promotion agreement (the “**Promotion Agreement**”), pursuant to which Beijing Sanyouli and Zhongli will collaborate on technology promotion in the following areas:

1. Both parties shall, upon approval, carry out technology application promotion services for the treatment of periodontitis using allogeneic dental pulp mesenchymal stem cell injections (the “**DPSC Project**”) within the Boao Lecheng International Medical Tourism Pilot Zone (the “**Pilot Zone**”) in Boao Town, Qionghai City, Hainan Province.

2. Upon obtaining the technical compliance approval and fee licensing from the Pilot Zone for the DPSC Project, Beijing Sanyouli shall recommend Zhongli to the cooperating medical institutions and commercial agents as the technology application promoter for the DPSC Project, to conduct worldwide promotion services related to the technological transformation and application of the project in accordance with national laws and regulations, and collaborate with Beijing Sanyouli and its partners to jointly undertake the technology promotion and commercialisation of the DPSC Project, including but not limited to project publicity, promotional activities, and market operation and expansion.

INFORMATION ON BEIJING SANYOULI

Beijing Sanyouli is a company established in the PRC in 2011 with limited liability. The company focuses on the research and development (“**R&D**”) of stem cell and biopharmaceuticals, with core business activities encompassing the development of cell therapy drugs and GMP cell preparation. Through joint R&D efforts with a technical team headed by Fellow Wang Songling (王松靈), an academician at the Institute of Oral Translational Medicine* (口腔轉化醫學研究所) of Capital Medical University, Beijing Sanyouli has established key technological platforms for the isolation, purification, in vitro culture, and long-term storage of DPSC. The DPSC Project developed by Beijing Sanyouli has obtained implied approval from the National Center for Drug Evaluation for Investigational New Drug (IND) and has completed Phase I clinical trials and IIT research. The results demonstrate that the DPSC Project has a favourable safety profile and is suitable for application and technology transfer in certain regions of the PRC where pilot trial permissions have been granted.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, each of Beijing Sanyouli and its ultimate beneficial owner is independent of, and not connected with, the Company or its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) as of the date of this announcement.

REASONS FOR AND BENEFITS OF THE PROMOTION AGREEMENT

The Company is a company incorporated in Bermuda with limited liability and acts as an investment holding company. Through its subsidiaries, it is principally engaged in the longevity science business, money lending & financial advisory services, and securities, property, and investment business. Zhongli is a company established in the PRC with limited liability, primarily engaged in the provision of longevity health services in the PRC.

The Board believes that the Promotion Agreement will be beneficial to the future business development of the Group by establishing a globally leading life sciences empowerment platform. This platform aims to integrate academic conferences, technology transformation, and industrial implementation into a unified ecosystem, thereby promoting deep collaboration among the industry, academia, and research institutions within the PRC's life sciences sector. The Promotion Agreement will further enhance the Group's presence in the fields of longevity science diagnostics and medical services, opening new revenue streams in longevity science for the Company. It is expected to contribute to more stable and sustainable revenue growth for the Group in the long term.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman and Executive Director

Hong Kong, 2 July 2025

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (Chairman)
Mr. Yan Yifan (Chief Executive Officer)
Mr. Li Xiaoshuang
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Lee See Barry
Mr. Huang Jiang
Prof. Huang Cibo

Non-executive Directors

Dr. He Yiwu
Mr. Lyn Changsheng

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.

* *For identification only*